M. Eisenberger

发表

Metastasis Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-Resistant Prostate Cancer

K. Pienta, P. Tran, T. DeWeese, 2020 .

Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805

E. Plimack, D. Cella, R. DiPaola, 2022, The Prostate.

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

E. Plimack, R. DiPaola, M. Carducci, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.

R. DiPaola, M. Carducci, M. Kohli, 2018, European urology.

Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial

Hao Wang, P. Tran, J. Hearn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Hao Wang, D. Song, P. Tran, 2019, BMC Cancer.

Phase II Trial of Amonafide for the Treatment of Advanced, Hormonally Refractory Carcinoma of the Prostate: A Southwest Oncology Group Study

I. Thompson, E. Crawford, M. Marshall, 1994, American journal of clinical oncology.

Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer

Z. Shun, O. Sartor, S. Oudard, 2022, Therapeutic advances in medical oncology.

Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial

R. DiPaola, M. Carducci, M. Kohli, 2016 .

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

B. Freidlin, H. Scher, W. Oh, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.

F. Meyers, E. Small, W. Slichenmyer, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined Carboplatin Plus Bleomycin and Conventional Radiotherapy for Advanced Carcinomas of the Head and Neck

M. Suntharalingam, O. Salazar, V. Sinibaldi, 1995, American journal of clinical oncology.